

CID Pharma needs EGP 500 mn to upgrade production lines to be GMP-compliant

CID Pharma needs an estimated EGP 500 million to upgrade its production infrastructure to meet Good Manufacturing Practice (GMP) standards, as it seeks to boost its exports. The state-owned drug company plans to spend EGP 100 million in 2020 to modernize production lines of hormone drugs, birth control pills, and oil ampoules.